Compounds and their uses for alleviating menopause-associated symptoms
The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.
1. A method of alleviating menopause-associated symptoms, comprising orally administering a composition comprising an estetrol component at a daily amount equivalent to about 15 mg of estetrol.
2. The method of claim 1 , further comprising administering a progestogenic component.
3. The method of claim 2 , wherein said progestogenic component is selected from drospirenone, progesterone and dydrogesterone.
4. The method of claim 2 , wherein said progestogenic component is progesterone and is administered at a daily dose of from 50 mg to 200 mg.
5. The method of claim 1 , further comprising administering bazedoxifene.
6. The method of claim 2 , wherein said progestogenic component is administered in the same composition as the estetrol component.
7. The method of claim 1 , wherein the estetrol component is estetrol.
8. The method of claim 1 , wherein the composition is formulated as an oral dosage unit.
9. The method of claim 8 , wherein the oral dosage unit is formulated as a daily dosage unit.
10. The method of claim 7 , wherein the estetrol is estetrol monohydrate.
11. The method of claim 5 , wherein said bazedoxifene is administered in the same composition as the estetrol component.